177 related articles for article (PubMed ID: 19739077)
1. Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity.
Pilzer D; Saar M; Koya K; Fishelson Z
Int J Cancer; 2010 Mar; 126(6):1428-35. PubMed ID: 19739077
[TBL] [Abstract][Full Text] [Related]
2. Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis.
Pilzer D; Fishelson Z
Int Immunol; 2005 Sep; 17(9):1239-48. PubMed ID: 16091382
[TBL] [Abstract][Full Text] [Related]
3. Mortalin/GRP75 binds to complement C9 and plays a role in resistance to complement-dependent cytotoxicity.
Saar Ray M; Moskovich O; Iosefson O; Fishelson Z
J Biol Chem; 2014 May; 289(21):15014-22. PubMed ID: 24719326
[TBL] [Abstract][Full Text] [Related]
4. Cooperation between Hsp90 and mortalin/GRP75 in resistance to cell death induced by complement C5b-9.
Rozenberg P; Ziporen L; Gancz D; Saar-Ray M; Fishelson Z
Cell Death Dis; 2018 Feb; 9(2):150. PubMed ID: 29396434
[TBL] [Abstract][Full Text] [Related]
5. Mortalin sensitizes human cancer cells to MKT-077-induced senescence.
Deocaris CC; Widodo N; Shrestha BG; Kaur K; Ohtaka M; Yamasaki K; Kaul SC; Wadhwa R
Cancer Lett; 2007 Jul; 252(2):259-69. PubMed ID: 17306926
[TBL] [Abstract][Full Text] [Related]
6. Complement membrane attack complex, perforin, and bacterial exotoxins induce in K562 cells calcium-dependent cross-protection from lysis.
Reiter Y; Ciobotariu A; Jones J; Morgan BP; Fishelson Z
J Immunol; 1995 Aug; 155(4):2203-10. PubMed ID: 7636268
[TBL] [Abstract][Full Text] [Related]
7. Regulation of Complement-Dependent Cytotoxicity by MicroRNAs miR-200b, miR-200c, and miR-217.
Hillman Y; Mazkereth N; Farberov L; Shomron N; Fishelson Z
J Immunol; 2016 Jun; 196(12):5156-65. PubMed ID: 27183614
[TBL] [Abstract][Full Text] [Related]
8. Rhodacyanine dye MKT-077 inhibits in vitro telomerase assay but has no detectable effects on telomerase activity in vivo.
Wadhwa R; Colgin L; Yaguchi T; Taira K; Reddel RR; Kaul SC
Cancer Res; 2002 Aug; 62(15):4434-8. PubMed ID: 12154051
[TBL] [Abstract][Full Text] [Related]
9. Complement triggers relocation of Mortalin/GRP75 from mitochondria to the plasma membrane.
Mazkereth N; Rocca F; Schubert JR; Geisler C; Hillman Y; Egner A; Fishelson Z
Immunobiology; 2016 Dec; 221(12):1395-1406. PubMed ID: 27475989
[TBL] [Abstract][Full Text] [Related]
10. SMR peptide antagonizes mortalin promoted release of extracellular vesicles and affects mortalin protection from complement-dependent cytotoxicity in breast cancer cells and leukemia cells.
Huang MB; Wu JY; Lillard J; Bond VC
Oncotarget; 2019 Sep; 10(52):5419-5438. PubMed ID: 31534628
[No Abstract] [Full Text] [Related]
11. Sublytic complement attack protects tumor cells from lytic doses of antibody and complement.
Reiter Y; Ciobotariu A; Fishelson Z
Eur J Immunol; 1992 May; 22(5):1207-13. PubMed ID: 1577063
[TBL] [Abstract][Full Text] [Related]
12. Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function.
Wadhwa R; Sugihara T; Yoshida A; Nomura H; Reddel RR; Simpson R; Maruta H; Kaul SC
Cancer Res; 2000 Dec; 60(24):6818-21. PubMed ID: 11156371
[TBL] [Abstract][Full Text] [Related]
13. Mortalin-based cytoplasmic sequestration of p53 in a nonmammalian cancer model.
Walker C; Böttger S; Low B
Am J Pathol; 2006 May; 168(5):1526-30. PubMed ID: 16651619
[TBL] [Abstract][Full Text] [Related]
14. Mortalin inhibition in experimental Parkinson's disease.
Chiasserini D; Tozzi A; de Iure A; Tantucci M; Susta F; Orvietani PL; Koya K; Binaglia L; Calabresi P
Mov Disord; 2011 Aug; 26(9):1639-47. PubMed ID: 21542017
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic sequestration of the tumor suppressor p53 by a heat shock protein 70 family member, mortalin, in human colorectal adenocarcinoma cell lines.
Gestl EE; Anne Böttger S
Biochem Biophys Res Commun; 2012 Jun; 423(2):411-6. PubMed ID: 22683628
[TBL] [Abstract][Full Text] [Related]
16. Withanone binds to mortalin and abrogates mortalin-p53 complex: computational and experimental evidence.
Grover A; Priyandoko D; Gao R; Shandilya A; Widodo N; Bisaria VS; Kaul SC; Wadhwa R; Sundar D
Int J Biochem Cell Biol; 2012 Mar; 44(3):496-504. PubMed ID: 22155302
[TBL] [Abstract][Full Text] [Related]
17. Relevance of mortalin to cancer cell stemness and cancer therapy.
Yun CO; Bhargava P; Na Y; Lee JS; Ryu J; Kaul SC; Wadhwa R
Sci Rep; 2017 Feb; 7():42016. PubMed ID: 28165047
[TBL] [Abstract][Full Text] [Related]
18. Emission of membrane vesicles: roles in complement resistance, immunity and cancer.
Pilzer D; Gasser O; Moskovich O; Schifferli JA; Fishelson Z
Springer Semin Immunopathol; 2005 Nov; 27(3):375-87. PubMed ID: 16189651
[TBL] [Abstract][Full Text] [Related]
19. Mortalin peptides exert antitumor activities and act as adjuvants to antibody-mediated complement-dependent cytotoxicity.
Jubran R; Saar-Ray M; Wawruszak A; Ziporen L; Donin N; Bairey O; Fishelson Z
Int J Oncol; 2020 Oct; 57(4):1013-1026. PubMed ID: 32700755
[TBL] [Abstract][Full Text] [Related]
20. Analogs of the Heat Shock Protein 70 Inhibitor MKT-077 Suppress Medullary Thyroid Carcinoma Cells.
Hong SK; Starenki D; Johnson OT; Gestwicki JE; Park JI
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
